目的　探讨红细胞补体受体Ⅰ型分子 (CR1)在肝癌疾病发生、发展中的意义。方法　采用聚合酶链反应 (PCR)和HindIII酶切技术测定红细胞CR1分子基因型 ,采用酶联法定量测定红细胞CR1分子的数量 ,以红细胞天然免疫粘附试验测定红细胞CR1分子粘附活性。结果　 10 4例肝癌患者红细胞CR1分子密度相关基因多态性分布 (HH :70 .2 % ,HL :2 4.0 % ,LL :5 .8% )与 75名正常人(HH :74.7% ,HL :2 1.3% ,LL :4.0 % )比较差异无显著意义 ;肝癌患者红细胞CR1分子的数量(0 .83± 0 .2 2 )及粘附活性 (4 7.1± 6 .5 )均显著低于正常人组 ,差异有非常显著意义 (1.2 6± 0 .33、6 2 .4±7.6 ,P <0 .0 1) ;并且CR1分子基因多态性为 :高表达的肝癌患者其红细胞CR1分子数量表达与粘附活性都明显下降 ;伴有肝功能明显异常的肝癌患者其红细胞CR1分子数量及粘附活性显著低于早期或肝功能正常的肝癌患者。结论　提示肝癌患者红细胞CR1分子数量及粘附活性的变化主要是后天因素引起 ,肝癌患者红细胞CR1分子数量及粘附活性的变化与病情发展及严重程度密切相关 Objective To investigate the significance of erythrocyte complement receptor type 1 (CR1) gene in the occurrence and development of liver cancer. Methods The genotypes of CR1 in erythrocytes were determined by polymerase chain reaction (PCR) and HindIII digestion. The number of CR1 in erythrocytes was quantitatively determined by enzyme-linked immunosorbent assay (ELISA). The adhesion activity of erythrocyte CR1 was determined by erythrocyte innate immunity adhesion assay. Results The distribution of erythrocyte CR1 molecular density related genes (HH: 70.2%, HL: 5.0%, LL: 5.8%) in 10 4 HCC patients and 75 normal persons (HH: 74.7% 2 1.3%, LL: 4.0%). The number of erythrocyte CR1 molecules (0.83 ± 0.22) and adhesion activity (4 7.1 ± 6.5) in HCC patients were significantly lower than those in normal subjects Group, the difference was significant (1.2 6 ± 0.33,6 2 .4 ± 7.6, P <0.01); and the CR1 gene polymorphism was: high expression of the number of red blood cells in patients with liver cancer CR1 expression And adhesive activity were significantly decreased; accompanied by significant abnormal liver function in patients with red cell CR1 molecular weight and adhesion activity was significantly lower than those with early or normal liver function in patients with liver cancer. The results suggest that the changes of the number and adhesion activity of erythrocyte CR1 in patients with hepatocellular carcinoma are mainly caused by acquired factors. The changes of the number of CR1 molecules and adhesion activity of erythrocytes in patients with hepatocellular carcinoma are closely related to the progression and severity of the disease